NYSE$MDT

Medtronic PLC · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

Medtronic's Q3 2021 financial results reflected a slight increase in revenue and a decrease in earnings per share.

Medtronic reported a Q3 revenue of $7.775 billion, a 0.8% increase as reported, but a 1.0% decrease organically. The GAAP diluted EPS was $0.94, while the non-GAAP diluted EPS was $1.29, both decreasing by 10%. The company's performance was impacted by the resurgence of COVID-19, which affected procedure volumes.

  • Q3 revenue increased 0.8% as reported, but decreased 1.0% organically.
  • GAAP diluted EPS was $0.94, while non-GAAP diluted EPS was $1.29, both decreasing by 10%.
  • U.S. revenue decreased 2%, representing 51% of the total revenue.
  • The company experienced growth in specific areas such as Leadless Pacemakers and Respiratory Interventions, while others like Coronary & Structural Heart faced declines.

Headline financials

Total Revenue

$7.78B

Previous: $7.72B+0.8%
EPS (adj)

$1.29

Previous: $1.44-10.4%
Organic Revenue Growth

-1.0%

Previous: 2.6%-138.5%
Capital Expenditures

-$978M

Previous: -$877M-11.5%
Free Cash Flow

$3.52B

Previous: $4.91B-28.3%
Net Income

$1.27B

Previous: $1.92B-33.7%
Operating Income

$1.28B

Previous: $1.64B-22.1%
Gross Profit

$5.15B

Previous: $5.32B-3.1%
Cash & Equivalents

$5.08B

Previous: $3.71B+36.9%
Total Assets

$97.3B

Previous: $92.8B+4.8%
Stock-Based Comp

$65M

Previous: $66M-1.5%

Revenue & EPS history

Medtronic · Revenue · Quarterly

$7.78B

Q3 2021+0.8%vs Q3 2020
Beat estimate in 14 of 16 quarters(88%)
ActualEstimate

Revenue by segment

Medtronic · $7.78B total across 9 segments · Q3 2021

  • Surgical & Endoscopy
    $1.42B-3.5%
  • Cardiac Rhythm & Heart Failure
    $1.37B-1.6%
  • Cranial & Spinal Technologies
    $1.08B+36.0%
  • Acute Care & Monitoring
    $890M
  • Coronary & Peripheral Vascular
    $873M-7.9%
  • Diabetes
    $630M+3.3%
  • Specialty Therapies
    $618M
  • Structural Heart & Aortic
    $463M-3.1%
  • Neuromodulation
    $426M+40.6%

Forward guidance

Medtronic is not providing formal annual or quarterly financial guidance at this time due to the uncertainty caused by the COVID-19 pandemic.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

-0.1%

Avg return

Earnings day

+0.2%

Avg return

5 days after

-1.4%

Avg return

30 days after

58%

38 / 66 earnings

Positive

+6.2%

Q1 2019

Best reaction

-7.3%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+5.3%+9.4%
Q3 2026-2.8%-2.6%-12.7%
Q2 2026+3.9%+5.1%+2.3%
Q1 2026-3.1%-0.1%+3.0%
Q4 2025-2.2%-6.6%-0.0%
Q3 2025-7.3%-3.1%-1.7%
Q2 2025-4.0%-1.6%-8.7%
Q1 2025+3.2%+4.2%+5.5%
Q4 2024-4.0%-4.4%-4.8%
Q3 2024+1.8%+1.5%-1.2%
Q2 2024+4.3%+5.1%+9.0%
Q1 2024+2.5%+0.7%-1.4%
Q4 2023-6.9%-5.7%-0.0%
Q3 2023+0.4%-1.5%-8.5%
Q2 2023-4.0%-3.9%-6.3%
Q1 2023-4.1%-3.9%-10.2%
Q4 2022-6.1%-5.1%-14.5%
Q3 2022+2.4%+5.2%+5.7%
Q2 2022-2.1%-5.0%-12.0%
Q1 2022+4.7%+4.1%+1.7%
Q4 2021+0.3%-0.8%+2.8%
Q3 2021+2.6%+1.1%+0.7%
Q2 2021+2.1%+3.3%+2.8%
Q1 2021+3.9%+7.7%+1.1%
Q4 2020-3.4%-0.9%-4.3%
Q3 2020-3.0%-3.5%-32.5%
Q2 2020+0.5%-0.4%+2.0%
Q1 2020+3.5%+1.8%+6.6%
Q4 2019+4.8%+2.9%+12.0%
Q3 2019+0.6%+1.6%-0.2%
Q2 2019+2.9%+1.8%-0.5%
Q1 2019+6.2%+6.1%+8.3%
Q4 2018+1.2%+0.2%+1.8%
Q3 2018-3.1%-3.5%-6.2%
Q2 2018+4.4%+5.5%+3.3%
Q1 2018-4.5%-5.3%-4.8%
Q4 2017+0.5%+0.2%+5.3%
Q3 2017+0.9%+2.7%+2.5%
Q2 2017-6.0%-6.3%-11.0%
Q1 2017-0.1%+0.2%+1.2%
Q4 2016-1.4%+1.5%+6.2%
Q3 2016-3.6%
Q2 2016+2.7%
Q1 2016-3.6%
Q4 2015+0.2%
Q3 2015+4.3%
Q2 2015+3.7%
Q1 2015+1.1%
Q4 2014-1.0%
Q3 2014-1.2%
Q2 2014-2.4%
Q1 2014-2.6%
Q4 2013+3.3%
Q3 2013-5.0%
Q2 2013+1.6%
Q1 2013+1.2%
Q4 2012+2.1%
Q3 2012+2.0%
Q2 2012-6.5%
Q1 2012-3.2%
Q4 2011+1.5%
Q3 2011+1.4%
Q2 2010-0.2%
Q1 2010+1.5%
Q4 2010+0.7%
Q3 2009+0.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro